DCGI green flag to Abbott heart failure, angina treatment drug Ivabradine
Abbott plans to launch Ivabradine prolonged-release tablets in the Indian market in the coming weeks.;
Advertisement
New Delhi: Global healthcare firm Abbott on Wednesday said it has received approval from the Drugs Controller General of India (DCGI) for its once-a-day formulation, Ivabradine, used for the treatment of chronic heart failure and chronic stable angina.
The company plans to launch Ivabradine prolonged-release tablets in the Indian market in the coming weeks, Abbott said in a statement.
This formulation will be more convenient for patients, which will help facilitate treatment adherence with the aim to improve health outcomes, it added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.